Product
IBI306
3 clinical trials
3 indications
Indication
HypercholesterolemiaIndication
Homozygous Familial HypercholesterolemiaClinical trial
A Randomized, Double-blind, Placebo-controlled, Repeated-dosing, Multiple Ascending Dose Trial to Evaluate the Safety and Tolerability of a Novel PCSK-9 Anti-body, IBI306, in Chinese Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2019-12-25
Clinical trial
A Study to Evaluate Safety and Efficacy of IBI306 in Patients With Heterozygous Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2021-06-30
Clinical trial
Phase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia.Status: Completed, Estimated PCD: 2021-12-30